Interstitial lung diseases (ILDs) represent a heterogeneous group of more than 200 lung disorders. Primarily affecting the pulmonary interstitium, these diseases are characterized by inflammation, fibrosis, or a combination of both. This article provides a comprehensive overview of ILDs, their pathophysiology, diagnosis, and management strategies.
ILDs are typically the result of an exaggerated or misdirected repair response to lung injury. Inflammatory cells infiltrate the interstitium, leading to fibroblast proliferation, collagen deposition, and eventual architectural distortion. This process results in impaired gas exchange, restrictive lung physiology, and respiratory failure if unchecked.
Diagnosis of ILDs requires a thorough clinical evaluation, including a detailed history and physical examination. High-resolution computed tomography (HRCT) is the imaging modality of choice, revealing characteristic patterns such as ground-glass opacities, reticulations, and honeycombing. Pulmonary function tests show a restrictive pattern with reduced diffusion capacity. Lung biopsy, though not always necessary, can provide definitive diagnosis in certain cases.
Management of ILDs is complex and multifaceted. It primarily focuses on halting disease progression and improving quality of life. Treatment options include corticosteroids, immunosuppressive agents, and antifibrotic drugs. Lung transplantation may be considered in advanced cases. Multidisciplinary team involvement is crucial for optimal patient care.
Interstitial lung diseases present a significant challenge due to their diversity and complex pathophysiology. Early recognition, accurate diagnosis, and appropriate management can significantly improve patient outcomes. As our understanding of these diseases continues to evolve, so too will our therapeutic strategies, underscoring the importance of ongoing research in this field.
1.
Toward rapid and comprehensive genetic diagnosis of pediatric cancer through adaptive sequencing
2.
Q&A: Why adolescents and young adults with cancer are falling behind
3.
Fixed-Duration Combo Shows Promise for Relapsed MCL
4.
Hospital receives 300 backpacks designed to help kids get leukemia treatment on the go
5.
A study has developed molecular markers that predict meningioma recurrence.
1.
Ultimate Guide to Oncology Services in the USA
2.
Exploring the Benefits of Teclistamab for Treating Advanced Cancer
3.
Glofitamab: A Breakthrough Therapy for Relapsed/Refractory Mantle Cell Lymphoma
4.
The Importance of Iron Rich Foods in Preventing and Treating Anemia
5.
Unexplained Weight Loss: Revealing Occult Cancers and Paraneoplastic Syndromes
1.
International Cancer Conference
2.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
3.
International Cancer Conference
4.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Updates on the First Line Management of ALK+ NSCLC
2.
Dacomitinib Case Presentation: Baseline Treatment and Current Status
3.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Continuation
4.
Optimizing Treatment Options in Advanced Urothelial Carcinoma
5.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part II
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation